CIK 0001438533
- Large accelerated filer
Travere Therapeutics, Inc.
Sign in to watch- Ticker
- TVTX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- CA
- Entity type
- Operating
- EIN
- 262383102
- Phone
- +1 888-969-7879
- Business address
- 3611 VALLEY CENTRE DR, SUITE 300, SAN DIEGO, CA, 92130
- Former names
- Retrophin, Inc., Desert Gateway, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $79,495,607
- in 10 filings, $79.5M under 10b5-1 plans
Net −$79,495,607. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Dube Eric M −$38.5M CHIEF EXECUTIVE OFFICER sold 60% of stake
- Heerma Peter −$17.9M EVP, CHIEF COMMERCIAL OFFICER sold 71% of stake
- ROTE WILLIAM E. −$13.1M Chief Research Officer sold 68% of stake
- Cline Christopher R. −$3.2M CHIEF FINANCIAL OFFICER sold 37% of stake
- Inrig Jula −$2.8M EVP, Head of R&D & CMO sold 31% of stake
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2019-05-15 | ASELAGE STEVE Director | Sale | −1,838 | $17.82 | $33K | 255,966 |
| 2019-05-14 | ROTE WILLIAM E. Senior Vice President, R&D | Sale | −813 | $17.78 | $14K | 18,997 |
| 2019-05-14 | REED ELIZABETH E SVP, GC & Corporate Secretary | Sale | −525 | $17.75 | $9K | 20,033 |
| 2019-05-14 | ASELAGE STEVE Director | Sale | −1,838 | $17.79 | $33K | 257,804 |
| 2019-05-13 | Poole Sandra Director | Grant or award | +3,500 | 3,500 | ||
| 2019-05-13 | Poole Sandra Director | Grant or award · Stock Option (Right to Buy) | +14,000 | 14,000 | ||
| 2019-05-09 | REED ELIZABETH E SVP, GC & Corporate Secretary | Grant or award | +6,000 | 20,558 | ||
| 2019-05-09 | REED ELIZABETH E SVP, GC & Corporate Secretary | Grant or award · Employee stock option (right to buy) | +40,000 | 40,000 | ||
| 2019-05-09 | REED ELIZABETH E SVP, GC & Corporate Secretary | Grant or award · Performance-based restricted stock units | +6,000 | 6,000 | ||
| 2019-05-09 | ROTE WILLIAM E. Senior Vice President, R&D | Grant or award | +6,000 | 19,810 | ||
| 2019-05-09 | ROTE WILLIAM E. Senior Vice President, R&D | Grant or award · Employee stock option (right to buy) | +40,000 | 40,000 | ||
| 2019-05-09 | ROTE WILLIAM E. Senior Vice President, R&D | Grant or award · Performance-based restricted stock units | +6,000 | 6,000 | ||
| 2019-05-09 | Rosenberg Noah L. Chief Medical Officer | Grant or award | +6,000 | 16,000 | ||
| 2019-05-09 | Rosenberg Noah L. Chief Medical Officer | Grant or award · Employee stock option (right to buy) | +40,000 | 40,000 | ||
| 2019-05-09 | Rosenberg Noah L. Chief Medical Officer | Grant or award · Performance-based restricted stock units | +6,000 | 6,000 | ||
| 2019-05-09 | Clague Laura Chief Financial Officer | Grant or award | +6,000 | 16,000 | ||
| 2019-05-09 | Clague Laura Chief Financial Officer | Grant or award · Employee stock option (right to buy) | +40,000 | 40,000 | ||
| 2019-05-09 | Clague Laura Chief Financial Officer | Grant or award · Performance-based restricted stock units | +6,000 | 6,000 | ||
| 2019-05-09 | Dube Eric M Chief Executive Officer | Grant or award · Performance-based restricted stock units | +6,000 | 6,000 | ||
| 2019-05-08 | Squarer Ron Director | Grant or award | +2,000 | 8,875 |
Page 46 of 51 · 1,020 trades